goralatide has been researched along with Alloxan Diabetes in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Goodwin, JE; Kanasaki, K; Koya, D; Srivastava, SP | 1 |
| Gao, R; Hu, Q; Kanasaki, K; Kitada, M; Koya, D; Li, J; Li, S; Liu, H; Srivastava, SP; Wu, G | 1 |
| Bernstein, EA; Bernstein, KE; Cao, DY; Eriguchi, M; Fuchs, S; Giani, JF; Gonzalez-Villalobos, RA; Khan, Z; McDonough, AA; Toblli, JE; Veiras, LC | 1 |
| Gao, R; Kanasaki, K; Kitada, M; Koya, D; Li, J; Okazaki, T | 1 |
| Ishigaki, Y; Kanasaki, K; Kanasaki, M; Kitada, M; Koya, D; Nagai, T; Nakamura, Y; Shi, S; Srivastava, SP | 1 |
| Haneda, M; Kanasaki, K; Kanasaki, M; Kitada, M; Koya, D; Nagai, T; Nitta, K; Shi, S; Srivastava, SP | 1 |
| Bombardi, C; Castoldi, G; Corradi, B; di Gioia, CR; Leopizzi, M; Mancini, M; Perego, C; Perego, L; Perlini, S; Stella, A; Zerbini, G | 1 |
7 other study(ies) available for goralatide and Alloxan Diabetes
| Article | Year |
|---|---|
Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Disease Models, Animal; Drug Synergism; Gene Expression Regulation; Humans; Mice; MicroRNAs; Oligopeptides; Signal Transduction; Transforming Growth Factor beta | 2020 |
Endothelial FGFR1 (Fibroblast Growth Factor Receptor 1) Deficiency Contributes Differential Fibrogenic Effects in Kidney and Heart of Diabetic Mice.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Endothelium; Epithelial Cells; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Kidney; Kidney Tubules, Proximal; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Oligopeptides; Receptor, Fibroblast Growth Factor, Type 1 | 2020 |
The Absence of the ACE N-Domain Decreases Renal Inflammation and Facilitates Sodium Excretion during Diabetic Kidney Disease.
Topics: Amino Acid Substitution; Angiotensin II; Animals; Catalytic Domain; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial Sodium Channels; Inflammation; Interleukin-1beta; Kidney; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutagenesis, Site-Directed; Natriuresis; Oligopeptides; Peptidyl-Dipeptidase A; Protein Domains; Renin-Angiotensin System | 2018 |
βklotho is essential for the anti-endothelial mesenchymal transition effects of N-acetyl-seryl-aspartyl-lysyl-proline.
Topics: Animals; Diabetes Mellitus, Experimental; Epithelial-Mesenchymal Transition; Growth Inhibitors; Klotho Proteins; Male; Membrane Proteins; Mice; Oligopeptides | 2019 |
N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition.
Topics: Animals; Cytokines; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial-Mesenchymal Transition; Fibrosis; Growth Inhibitors; Male; Mice; MicroRNAs; Oligopeptides; Receptors, Fibroblast Growth Factor | 2014 |
Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Imidazolidines; Mice; Mice, Inbred NOD; Oligopeptides; Peptidyl-Dipeptidase A | 2016 |
Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus, Experimental; Fibrosis; Heart Ventricles; Hypoglycemic Agents; Insulin; Male; Myocardium; Oligopeptides; Ramipril; Rats; Rats, Sprague-Dawley; Smad Proteins; Transforming Growth Factor beta1 | 2009 |